■ BACKGROUND
At present there is still no long-term sustainable culture system for Plasmodium vivax, the parasite responsible for 47% of malaria outside of sub-Saharan Africa.
1 P. vivax malaria, which can be fatal and is endemic in 57 countries, 1 is primarily treated with chemotherapy. Chloroquine plus primaquine is used in many areas of the world, such as South America, where resistance is not widespread, 2 while artemisinin-based combination therapies (ACTs) are used in high-transmission areas, such as Papua New Guinea, where chloroquine-resistant P. vivax has been observed. 3 Antifolates, such as the sulfadoxinepyrimethamine combination (Fansidar), are not recommended for use because of widespread parasite resistance but have been used extensively in the past. Pyrimethamine was added to table salt in some countries, including Brazil in the 1950s. 4, 5 Although P. vivax alleles conferring resistance to pyrimethamine are well known 6−9 and are found in the Amazon basin, alleles conferring resistance to chloroquine, artemisinin, and primaquine (the only therapy that prevents vivax malaria relapse) in P. vivax remain obscure.
To improve surveillance for drug resistance and to prevent complications from treatment with inadequate therapies it would be desirable to identify molecular markers of drug resistance. However, the lack of long-term culture methods for P. vivax complicates the identification of resistance genes using in vitro evolution or genetic crosses. On the other hand, given that there is no shortage of patients with P. vivax malaria, population genetic studies may provide an attractive method for mapping genes involved in drug resistance. In fact genomewide association studies were recently used to identify loci involved in P. falciparum artemisinin resistance. 10−13 Although population-based approaches are theoretically possible with P. vivax, to utilize these techniques it would be desirable to understand the frequency of polyclonal infections, levels of population structure, and rates of parasite inbreeding in different locations as this can affect the design of populationbased studies.
Although researchers have sought to address such questions about P. vivax populations using microsatellite markers and P. vivax DNA derived from patient infections, microsatellite markers are genetically less stable than single nucleotide variants (SNVs) and may provide overestimates of genetic diversity. Conversely, reliance on too few microsatellite markers may underestimate diversity, especially in closely related parasites. 14 Here we use next-generation sequencing (NGS) to analyze the genomes of P. vivax parasites collected from patients in an isolated mining camp in Peru, a country that has experienced a resurgence in malaria cases over the last half a century following near elimination. 15, 16 Even with a small sample size we find evidence of intrainfection polyclonality, interinfection clonality, and inbreeding, all factors that could affect sample size calculations in genetic mapping studies. Despite a relatively homogeneous population, we nevertheless find evidence of recent evolution in known drug-resistance genes, indicating that the direct examination of genome sequences and candidate drug-resistance genes may provide insight into the genetic basis of drug resistance in this parasite.
■ RESULTS AND DISCUSSION
Whole Genome Sequencing Identifies Polyclonality in the Madre de Dios Region. To investigate parasite genetic diversity and clonality in the Peruvian Amazon, 10 human whole blood samples (Mdio01, Mdio03−11) were collected from P. vivax-infected patients presenting to a local health post in the Madre de Dios region of Southeastern Peru (Table S1 ). Blood was drawn from patients and filtered with CF11 cellulose powder (Whatman) to remove human white cells before DNA isolation. Microsatellite analysis was first performed at five markers to establish a baseline understanding of the clonality for each sample (Table 1) , and then whole genome sequencing was performed to further investigate the composition of the samples. Illumina paired-end sequencing yielded a mean coverage of 10.7× per sample with an average of 29.2% of the reads aligning to the P. vivax Sal1 reference genome. Because of the poor coverage in four of the samples, they were not included in further whole genome analysis. The six samples (Mdio03, 05, 06, 08, 10, and 11) used for subsequent analysis had a mean coverage of 16.6× (Table 2 ).
All 10 samples were used for microsatellite analysis, and 4 of these samples (Mdio04, 6, 8, and 9) had multiple microsatellite repeat sizes suggesting preliminary evidence of polyclonality in these infections (Table 1) . Polyclonal infections could arise from mosquito injection of sibling parasites derived from a single meiosis into a person, from "superinfection" from multiple infectious mosquito bites, with each delivering subsequent genetically unrelated parasites, or from a combination of a relapse and a new infection. To gain further insight into the cause of polyclonality in these samples we genotyped each strain at 14 651 polymorphic sites that were confidently called in all samples (Methods , Table S2 ). Of these, a mean of 11 665 sites were polymorphic per sample (Table 3) .
Within a given sample, many polymorphic sites had mapped reads bearing two different alleles (mixed reads, designated the major and minor alleles based on read frequency), suggesting that the infection consisted of more than one parasite clone. The NGS data showed that all samples carried mixed-allele polymorphisms, ranging from 6% of genotyped sites in Mdio3 to 28% of the sites in Mdio10, compared to the microsatellite data, which showed that only two of the six high-coverage samples were polyclonal. We additionally calculated the withinhost diversity metric, F ws , 17, 18 an indicator of the multiplicity of infection (MOI) that considers the relative proportions of clones within a sample as well as the genetic divergence of the sample from the local parasite population. This metric is more robust to locus-specific artifacts that may occur using microsatellite analysis to calculate MOI. The F ws for the Madre de Dios isolates was between 0.46 and 0.83 (Table 3) , where values ≤0.7 are considered highly diverse. We previously observed F ws metrics between 0.97 and 0.94 for monoclonal P. vivax relapse infections.
14 Thus, these data suggest that the Madre de Dios infections may be polyclonal, particularly Mdio10, which has the lowest F ws and the greatest number of polymorphic sites in the genotyped set.
Madre de Dios P. vivax Genomes Are Composed of DNA from Three Hypothetical Haplotypes. Previous population studies of P. vivax, specifically those in the Peruvian Amazon, have revealed substantial genetic diversity among parasite populations with the vast majority of every infection examined appearing to be composed of a different haplotype using tandem repeat polymorphic markers.
19−21 Indeed our a Four samples (Mdio01, Mdio04, Mdio07, and Mdio09) were excluded from genotyping studies because the P. vivax read coverage was low. This is most likely due to high levels of contaminating human DNA or in the case of Mdio01, contamination with P. falciparum DNA.
microsatellite analysis using just four markers (excluding 4.2771 which was polyclonal) showed a unique haplotype for each of the samples tested in our small population. Because the transmission of malaria in Madre de Dios is not expected to be high, we would expect the parasites genotyped here to be more closely related. Therefore, we assessed the relatedness of the parasites comprising each infection. Principle component analysis (PCA) using the 14 651 genotyped sites showed that the Mdio06 and Mdio08 infections were nearly identical ( Figure 1A ). Furthermore, although Mdio05 and Mdio10 are somewhat unrelated when considering all alleles, they are nearly indistinguishable if polyclonal sites are excluded ( Figure 1B ) or if only the major allele is considered for the PCA ( Figure 1C ). The data suggest the clones present at the highest frequency in the Mdio05 and 10 infections are nearly identical but that the minor allele clones are different. When comparing the Madre de Dios population with other global P. vivax isolates (from Brazil, India, North Korea, Mauritania, 22 Peru, 23 and East Africa 14 ) , PCA showed that all six Madre de Dios samples were very closely related, even when considering Brazil I and IQ07, both P. vivax isolates from the Amazon basin ( Figure 1D ).
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Given the similarity of the population as a whole, we further sought to determine if the parasites would share chromosomal regions containing identical alleles, interspersed with unrelated regions, suggestive of sexual recombination. We performed pairwise comparisons of allele composition along each chromosome using the set of 9499 SNVs with no minor allele ( Figure 2A ). These data supported the PCA clustering data showing that Mdio06 and Mdio08 and Mdio05 and Mdio10 were closely related. Additionally, of the 5071 sites that were identical within the set of 6 sequences (and the nonancestral allele), most were spatially clustered along the chromosomes, indicating linkage. For example, Mdio03, 05, 10, and 11 are virtually identical to one another on chromosome 1: Mdio10 and Mdio11 differ at only 10 of 449 genotyped sites in contrast to Mdio08 and Mdio11, which differ at 231 of the 449 sites. In contrast, Mdio08 shares the same haplotype with Mdio06, Mdio05, and Mdio11 in parts of chromosomes 4 and 6.
The data also show evidence of meiotic recombination among the haplotypes as was previously shown.
14 To determine the number of founding parasites that may have contributed to the Madre de Dios breeding populations, we examined blocks of co-inherited markers (Methods). We found that 8.2 million bases (26% of the genome) were in regions that were identical across all isolates (a single haplotype). On the other hand, 43 and 25% of the genome ( Figure 2B ) were composed of two and three haplotypes, respectively. The remaining 6% of the genome contained four or five haplotypes. Six haplotypes (the maximum number that can be observed) were never observed. The isolated regions with more than three haplotypes typically spanned likely recombination junctions, were in regions containing known polymorphic genes, or were in genomic regions bearing signatures of a possible genome amplification event (see below). For instance, of the 10 allelic differences between Mdio10 and Mdio11 on chromosome 1, 3 are in a polymorphic gene (PVX_093645, bp 717 749 to 728 479) that contains 12 coding and noncoding substitutions. Mdio03 had the most SNVs that were present in only one strain (unique SNVs, Table 3 ), and it had only seven. These data suggest that two to three parasites contributed to a recombining parasite population in Madre de Dios and that differences observed within these parental genotypes are due to intrinsic mutation rates.
Exploration of Orthologs of Known Drug-Resistance Genes and Identification of Potential Novel ResistanceAssociated Genes. We also examined orthologs of known drug-resistance genes in P. falciparum to determine if any of these genes in P. vivax showed evidence of selection. All P. vivax malaria patients are currently treated with primaquine and chloroquine in Peru (CQ 25 mg/kg, PQ 0.5 mg/kg for 7 days), 24 although chloroquine resistance is found in the Amazon region and contributes to treatment failure in some countries. 25−27 The genes involved in chloroquine resistance in P. vivax are unknown, but good candidates include the orthologs of the P. falciparum genes that are involved in resistance, the chloroquine resistance transporter (pvcrt-o, PVX_087980), and the multidrug resistance transporter (pvmdr1, PVX_080100) ( Table 4 ). Pvmdr1 (T958M) bore a single variant relative to the SalI reference sequence; this same allele change has arisen, presumably independently in Thailand 28 and in Madagascar. 29 We found no coding changes in pvcrt-o, although no exonic coding changes in pvcrt-o have been observed even in parasites resistant to chloroquine. 29 Nevertheless, we did find six intronic changes and one mutation in 5′ UTR, placing it in the top 1% of genes with intronic changes (Table 4) . Interestingly, increased expression of pvcrt-o in chloroquine-resistant parasites from the Amazon has been observed. 30 Furthermore, we found no amino acid changes in the mitochondrially encoded gene, plviomp3, which encodes the cytochrome bc1 complex, the target of atovaquone in P. falciparum. 31 We also found no nonsynonymous mutations relative to SalI in pvkelch13 (PVX_083080), the P. vivax ortholog of pf kelch13, 10 a gene conferring reduced sensitivity to artemisinin in P. falciparum (reviewed in ref 32) presumably because ACTs are not currently used in the Amazon region.
A number of coding changes were observed in the P. vivax multidrug resistance associated protein (pvmrp1, PVX_124085), which bore nine nonsynonymous SNVs and two synonymous SNVs (Table 4) . Position 1466K variants are associated with antifolate resistance in P. falciparum, 33 and the disruption of this gene in P. falciparum leads to increased primaquine sensitivity. 34 Pvmrp1 was previously noted because of an unexpectedly high number of coding variants observed in another South American P. vivax patient isolate. 23 A homology model using the Caenorhabditis elegans multidrug resistance protein, PGP-1, 35 shows several of the mutations observed in the Madre de Dios population occurring in structurally conserved regions of the protein including the nucleic acid binding domain in the intracellular space (Figure 3) .
Although antifolates are no longer recommended in Peru we found that coding mutations in the antifolate pathway were common, with all isolates carrying the S117N and S58R dihydrofolate reductase (dhfr) mutations, known in combination to confer high levels of resistance to pyrimethamine in P. vivax (Table 4) . 8, 36 Notably, we found two independent S58R nucleotide transversions (C → A, C → G). Triallelic mutations are a feature shared by only 19 other genes, including the apical merozoite antigen (ama-1; PVX_092275) (Table S3) , suggesting selection pressure on this nucleotide position. A subset (Mdio05 and Mdio10) also carried the I173L allele associated with treatment failure. 36 Given how different these strains are from those in other countries ( Figure 1D ), it is expected that these mutations arose independently and were not imported. We found there were no novel variants in dihydropteroate synthetase (dhps; PVX_123230) or GTP cyclohydrolase (gtpch; PVX_123830), other genes in the dihydrofolate biosynthesis pathway.
It has been shown, on the basis of mapping study experiences with chloroquine-and pyrimethamine-resistant P. falciparum field isolates, that patterns of linkage for disequilibrium could be used to detect genes conferring drug resistance. 37, 38 These studies have indicated that genes involved in antifolate and chloroquine resistance have arisen infrequently and have likely been transmitted through populations by selective sweeps. 37, 38 In contrast to what was observed for P. falciparum, the region around dhfr on chromosome 5 (pvdhf r, bp 964 590 to 966 464) did not show strong evidence of linkage disequilibrium within the Madre de Dios parasite genomes (an 80 kb surrounding region showing two haplotypes is displayed in Figure 4) , suggesting that mutant pvdhf r has arisen more than once.
Evolution of Other Genes. To further identify genes under selection and potential genes not known to be involved in drug resistance we identified genes with a high nonsynonymous substitution to synonymous substitution ratio (K a /K s ). Of the top 20 genes with high K a /K s , 18 are hypothetical, reflecting the lack of information about the interaction of P. vivax with the human immune system. Those genes with functional annotations typically played possible roles in immune evasion, including members of the msp3 multigene family (Table S4) , as well as PVX_092625 which encodes an uncharacterized protein, the ortholog of a possible P. falciparum vaccine candidate, predicted to be surface expressed. 39 No statistically significant K a /K s ratios were observed for orthologs of known P. falciparum drug-resistance genes (Table S5) . The majority of genes (3773 out of 5507 queried), on the other hand, had no nonsynonymous variants in any of the isolates, reflecting the overall lack of diversity in the population.
Genome Regions around pvmrp1 and Genes of the Folate Biosynthetic Pathway Show Evidence of Gene Amplification. Changes in the gene copy number have been shown to or are predicted to confer drug resistance in laboratory-evolved P. falciparum clones 40 and P. falciparum field isolates 41 and are relatively common. We thus looked for potential increased read coverage across the genome in the Madre de Dios P. vivax sequences using an automated CNVcalling algorithm. 42 On average, 2.8% of the genome was potentially amplified and 1.5% showed evidence of a deletion event ( Figure 5A ). Deleted regions typically encoded members of multigene families. For example, a 100 kb region on chromosome 12 encodes members of the PfamD family, early transcribed membrane proteins, and exported proteins. An ∼200 kb region on chromosome 3 was deleted in Mdio5, Mdio6, and Mdio10 and encoded ∼15 VIR proteins, 7 plasmodium exported proteins, a PfamD family protein member, and an early transcribed member protein as well as "hypothetical" proteins.
In contrast to what is found in P. falciparum 43, 44 and P. vivax in Thailand 45 we found little evidence of increased read coverage near pvmdr1 on chromosome 10 (361 701−366 095) nor could we find evidence of an amplification event near pvcrto (chr1:330 260 to 334 540). On the other hand, the region around pvmrp1 (chr14:2 042 042−2 048 077) in Mdio06, Mdio08, and Mdio05 has increased read coverage suggestive of a copy number variant in that region ( Figure 5B ). Although amplification of this gene in P. vivax or P. falciparum patient isolates have not been reported, P. falciparum parasites exposed to atovaquone in the laboratory also acquired a CNV that encompassed this gene, 46 providing some evidence that extra copies provide an adaptive advantage.
Our data showed that pvdhf r is contained within a region with significantly increased read coverage in Mdio08 ( Figure  5C ), and manual inspection also showed increased read coverage in Mdio06. In addition, we also found that four isolates had significantly increased read coverage around the P. vivax dihydrofolate synthase gene (pvdhfs; PVX_116635), which encodes the protein upstream of dihydrofolate reductase in the folate biosynthesis pathway and converts 7,8-dihydropteroate, and L-glutamate to 7,8-dihydrofolate through the hydrolysis of ATP. Recombination events surrounding smaller amplified regions (e.g., 2 kb) were conclusively observed upstream and downstream of pvdhf r, suggesting that the genome may have harbored a large 30−40 kb amplification at one time, but the amplified region may have been partially Amplified regions with no clearly known drug-resistance genes were also observed (Table S6 ) and could represent novel resistance markers. Examples of such amplified regions include chromosome 1:473 919−541 139 bp and a number of regions on chromosome 3 that were observed in all but Mdio03. Although sequencing coverage is too low to establish exact boundaries of these events, one possibly interesting gene that was potentially amplified in this region is PVX_000585, which is predicted to encode a homologue of the E. coli multidrug transporter, EmrE. This membrane protein exchanges small aromatic drugs such as ethidium bromide and methyl viologen (paraquat) across the membrane in E. coli 47 and belongs to the same transporter class as pfcrt. 48 Orthologs are missing from most eukaryotes but are found in other apicomplexan parasites such as Toxoplasma gondii and Babesia bovis (OrthoMCL DB v.5.0). Further work will be needed to establish whether these changes are significant.

■ CONCLUSIONS
Our data highlight potential challenges with using genetic mapping methods to identify genes involved in antimalarial drug resistance. These include inbred populations, which can skew the true diversity of the population if diversity is measured by only a few markers; polyclonal infections, which can affect SNV calling and haplotype inference; and the appearance of de novo mutations which may or may not be associated with resistance in an otherwise homogeneous genetic background. In addition, genome amplifications, which may or may not be correctly mapped to their correct genome location, are likely to be common. All of these features may impact the study design.
On the other hand, our studies demonstrate that insight into the genetic basis of drug resistance can be gained simply by examining the genomes of parasites using high-resolution methods. This method was previously used to identify alleles associated with resistance to the antibiotic clindamycin in P. falciparum isolates from Peru 49 and GTP cyclohydrolase gene amplification events in many laboratory and field isolates. The GTP cyclohydrolase event was hypothesized to confer resistance to antifolate drugs because of its presence in the folate biosynthetic pathway 50, 51 and was eventually shown to help parasites survive exposure to antifolate drugs by increasing drug flux through the pathway in the presence of mutations in pfdhfr that cause a loss of fitness. 52 In our study we identify known and novel mutations potentially involved in drug resistance. Relatively uncharacterized genes that could be further tested for association with resistance to currently used therapies (primaquine and chloroquine) include pvmrp1 as well as PVX_000585, the P. vivax homologue of the Escherichia coli multidrug resistance gene, EmrE.
Genes involved in resistance to small molecules are now routinely found in P. falciparum using laboratory evolution and whole genome sequencing. 53 Identification of these genes allows for monitoring of the emergence of drug resistance in parasite populations. Additionally, knowledge of resistance genes can aide in the design of novel molecules that are effective at targeting the known target in the presence of these known population variants. The identification of resistance genes using laboratory evolution relies on in vitro culture systems and would be challenging for P. vivax. On the other hand, because parasites in a region such as Madre de Dios could effectively be clonal, such isolated parasite populations might offer opportunities to directly observe the effects of drug exposure on the population. Alleles that appeared in the population only after a new therapy was introduced might be readily identified in an inbred parasite population such as this. Thus, archiving parasite material before and after the introduction of a new therapy could eventually give valuable insight into the evolution of drug resistance in the field.
Our studies also have implications for the design of clinical trials aiming to test novel radical cure drugs that might replace primaquine, the only licensed drug that can eliminate dormant P. vivax and P. ovale hypnozoites. Although initial clinical trials might be performed with travelers or soldiers returning from endemic regions, groups that would not be expected to be reinfected, larger patient studies in endemic regions could be complexif a patient returned with an infection that was genotypically very similar to his original infection, then one might assume that the drug candidate was not effective at preventing relapse when in fact the patient had actually been reinfected. Thus, estimates of the number of parasite haplotypes circulating in a region would be needed before trials could be effectively designed. This method would be particularly suited for an area where transmission is low and thus less parasite diversity is expected. In regions where diversity is high and patients are infected with multiple strains, it may prove more difficult to observe mutations related to drug pressure.
■ METHODS Sample Collection. This study was approved by the Human Subjects Protection Program of the University of California San Diego, the Institutional Review Board of NAMRU-6, Lima, Peru and the Directorate of Health, Madre de Dios, Peru. Peripheral blood samples for next-generation sequencing were collected from patients with self-reported fever and microscopy-confirmed P. vivax malaria. Patients presented at the Peruvian Ministry of Health facility of Bajo Puquiri, locally called Delta-1, in the Madre de Dios department, Peru. This location is approximately 8 h from the capital city of Puerto Maldonado, over difficult terrain. P. vivax monoinfection was later confirmed by PCR as previously described. 54 Blood was collected using EDTA-containing Vacutainer tubes. Tubes were centrifuged at 1000g to remove plasma, and the packed red blood cells were resuspended in a 2× volume of sterile phosphate-buffered saline (1.8 mM KH 2 PO 4 , 10 mM Na 2 HPO 4 , 137 mM NaCl, 2.7 nM KCl). Within 1 h of collection diluted blood was filtered through CF11 cellulose powder (Whatman) to remove white blood cells. 55 Eluted blood was pelleted by centrifugation at 1000g for 10 min and stored at −20°C for a maximum period of 2 to 3 weeks before being shipped in batches to the NAMRU-6 laboratory in a liquid-nitrogen dry shipper.
Microsatellite Analysis. P. vivax microsatellite characterization was conducted using the following previously published loci: 14.185, 12.335, 7.67, 6.34, 4.2771, and 3.35. 56, 57 Microsatellites were amplified with primers previously described, 56 and fluorescently labeled PCR products were analyzed on an Applied Biosystems Prism 3130xl Avant Genetic Analyzer (Applied Biosystems). A minimum peak height of 200 fluorescent units was used to define amplification products.
Whole Genome Sequencing. Genomic DNA was isolated from frozen whole blood samples using a DNeasy blood and tissue kit (Qiagen), and whole genome paired end-sequencing libraries were created using the NEBNext DNA library prep kit (New England Biolabs). DNA was sheared using Covaris adaptive focused acoustics and size selected on an agarose gel. DNA libraries were clustered and run on an Illumina HiSeq2000 (Illumina, Inc., San Diego) according to the manufacturer's instructions. Base calls were made using Consensus Assessment of Sequence and Variation v. 1.8.2 (Illumina). Sequencing reads in fastq format are available on the National Center for Biotechnology Information's short read archive (PRJNA272364). Reads were aligned to the P. vivax SalI reference (v. 10.0) using the Burrows-Wheeler aligner with the default options. 58, 59 Picard was used to remove PCR duplicates and evaluate the sequencing quality.
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Single nucleotide variants (SNVs) were called simultaneously in the Madre de Dios set of 10 using the Genome Analysis Toolkit Unified Genotyper tool. Variant sites within SNV clusters (cluster window = 10, SNP cluster = 3) and with low mapping quality (MQ < 50) were filtered out. Additionally, variant sites with a combined depth of coverage of less than 20 reads (DP < 20) were excluded. A total of 32 199 high-quality SNVs were identified and genotyped in each of the 10 samples. Because we were interested in high-quality SNVs that would allow us to determine relatedness of the strains, we further filtered the variants. Overall read coverage was low in Mdio01, Mdio04, Mdio07, and Mdio09; therefore, these samples were excluded from further analysis. For the samples included, Mdio03, Mdio05, Mdio06, Mdio08, Mdio10, and Mdio11, sites were filtered if they did not have calleable alleles in all of these samples or a read coverage of <5. Additional custom filtering was designed to retain sites where we were confident of the zygosity. Homozygous SNVs were called if >80% of the reads were the major allele, and heterozygous SNVs were called if 50−80% of the reads represented the major allele. SNVs with more than one alternate allele were also excluded. This resulted in 15 380 confidently calleable sites for determining clonality located on both contigs and chromosomes. SNVs indentified in contigs were further removed to yield a high-quality set of 14 651 genotyped sites (Table 4) .
Diversity and Relatedness Analyses. To characterize within-host diversity we used the F ws statistic 18, 55 (F ws = 1 − (H w /H s ), where H w is the within-host heterozygosity and H s is the population-level heterozygosity), using the 14 651 genotyped sites. The principle component analysis was performed using the Matlab (R2012b, The Mathworks) princomp command. Calculation of the ratio of the nonsynonymous substation rate to the synonymous substitution rate (K a /K s ) was done using the modified Yang−Neilsen algorithm. 60 Haplotype blocks were calculated using a set of 4430 SNVs with no minor allele and which were variant in one Madre de Dios isolate relative to the others. The number of haplotypes present was calculated for 50 kb windows (moving over each chromosome in 5 kb steps) by calculating the pairwise distance matrix for all sample pairs within the window. The pairwise distance estimate, d, was calculated as d = n d /n c , where n d is the number of nonidentical sites and n c is the number of sites compared. Values for the distance matrix that were less than 5 × 10 −5 were considered to be similar haplotype blocks between samples.
Pairwise Comparisons. Pairwise comparisons were completed using either all 15 380 genotyped sites or sites where no minor allele was shared (9571 sites left). Chromosome maps were made to represent whether alternate alleles were shared between samples.
Homology Modeling. Amino acid sequences of PvMRP1 were retrieved from PlasmoDB (search ID: PVX_124085) and were cross referenced with Uniprot. A template search was conducted against the SWISS-MODEL template library, with the highest scoring template being chosen for model building. A web-based homology model was produced using the SWISS-MODEL pipeline which operates via Promod-II and Modeler platforms. The PyMOL Molecular Graphics System (version 1.3, 2010 Schrodinger, LLC.) was then used to display and label the protein structure.
CNV Analysis. Plasmodium Type Uncovering Software (Platypus) 61 was used to identify regions of the genome where a significant increase or decrease in read coverage was observed. This software sensitively detects the largest changes in read signal after GC bias normalization. Changes were also observed for the various unassembled contigs (data not shown).
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Demographic characteristics of the sample population. Table S1 . Demographic characteristics of the sample population, with units separate for each row. 10 patients were analyzed, with mean patient age and sex as well as previous malarial history and current clinical correlate listed. Table S5 . Ka/Ks ratios for P. vivax orthologs of known P. falciparum drug resistance genes. Calculation of substitution rates was done using the modified version of the Yang-Neilsen algorithm. SYN, number of synonymous changes; NON-SYN, number of non-synonymous changes.
